Testing effectiveness (Phase 2)WithdrawnNCT00408967
What this trial is testing
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
Who this might be right for
Ovarian Cancer
EMD Serono